State of New Jersey Common Pension Fund D increased its holdings in Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 7.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,300 shares of the biopharmaceutical company’s stock after purchasing an additional 4,457 shares during the period. State of New Jersey Common Pension Fund D owned 0.13% of Emergent BioSolutions worth $1,996,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in EBS. State of Alaska Department of Revenue grew its holdings in Emergent BioSolutions by 1.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 33,825 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 430 shares during the period. Covestor Ltd increased its position in Emergent BioSolutions by 43.8% during the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 491 shares during the last quarter. Kendall Capital Management raised its stake in Emergent BioSolutions by 4.7% during the first quarter. Kendall Capital Management now owns 11,585 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 525 shares during the period. Centaurus Financial Inc. boosted its holdings in shares of Emergent BioSolutions by 14.4% in the 2nd quarter. Centaurus Financial Inc. now owns 4,342 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 546 shares during the last quarter. Finally, Greenwood Capital Associates LLC grew its stake in shares of Emergent BioSolutions by 3.6% during the 1st quarter. Greenwood Capital Associates LLC now owns 16,067 shares of the biopharmaceutical company’s stock valued at $660,000 after buying an additional 554 shares during the period. 81.54% of the stock is currently owned by institutional investors and hedge funds.
Emergent BioSolutions Stock Performance
Emergent BioSolutions stock opened at $12.85 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.38 and a current ratio of 3.92. Emergent BioSolutions Inc. has a one year low of $12.00 and a one year high of $52.28. The stock’s 50 day moving average price is $20.87 and its 200 day moving average price is $27.60. The firm has a market capitalization of $640.73 million, a PE ratio of 7.60 and a beta of 1.04.
Analyst Ratings Changes
Emergent BioSolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
- EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
- DoorDash Outperforms Despite Losses – Is It Time To Buy?
- Analysts Rate DraftKings a Moderate Buy As Growth Slows
- Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.